logo part

proactive live

Get the stories as they are published

13 hours, 2 minutes ago

Kazia Therapeutics grants Oasmia exclusive rights for first-in-class ovarian cancer drug candidate Cantrixil

Oasmia Pharmaceutical AB will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.

Kazia Therapeutics Ltd has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB for Cantrixil (TRX-E-002-1), a clinical-stage, first-in-class drug candidate under development for the treatment of ovarian cancer.
13 hours, 37 minutes ago

Euro Manganese target price more than doubled by Canaccord Genuity

Canaccord has lifted EMN’s price target to A$1.30 (from A$O.55) and has maintained a speculative buy recommendation.

14 hours, 22 minutes ago

Red River Resources pours first gold at Hillgrove Mine and ramps up production

The pour is a key step in the company’s strategy to build a multi-asset operating business focused on precious and base metals with the objective of delivering prosperity through lean and clever resource development.

14 hours, 26 minutes ago

Andromeda Metals passes key milestone by submitting mining lease application for Great White Kaolin Project

Lodgement of the applications with the South Australian Government represents a milestone for the company which is focused on the commencement of operations in February 2022.

14 hours, 46 minutes ago

Coffee with Samso: Finding nickel sulphide in Tanzania - Adavale Resources

The electric vehicle revolution has thrown the world of battery metals, including nickel, into another rush for good assets.